<?xml version="1.0" encoding="UTF-8"?>
<ref id="B26">
 <label>26.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Xia</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Xu</surname>
    <given-names>W</given-names>
   </name>
   <name>
    <surname>Lan</surname>
    <given-names>Q</given-names>
   </name>
   <name>
    <surname>Feng</surname>
    <given-names>S</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.</article-title>
  <source>
   <italic>Cell Res.</italic>
  </source> (
  <year>2020</year>) 
  <volume>30</volume>:
  <fpage>343</fpage>â€“
  <lpage>55</lpage>. 
  <pub-id pub-id-type="doi">10.1038/s41422-020-0305-x</pub-id>
  <?supplied-pmid 32231345?>
  <pub-id pub-id-type="pmid">32231345</pub-id>
 </mixed-citation>
</ref>
